Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.404 5-летний Импакт фактор: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Том 40, 2020 Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v27.i4.20
pages 303-318

Botulinum Neurotoxin Vaccines: Past, Present, and Future

Leonard A. Smith
Integrated Toxicology Division, US Army Medical Research Institute of Infectious Diseases; Fort Detrick, MD 21702-5011, USA
Janice M. Rusnak
Special Immunizations Program, US Army Medical Research Institute of Infectious Diseases; Fort Detrick, MD 21702-5011, USA

Краткое описание

In the early 1930s, a formalin-inactivated toxoid against botulinum neurotoxin was first tested in humans. In 1965, a pentavalent botulinum toxoid (PBT) received Investigational New Drug (IND) status under the Centers for Disease Control's IND 161 (for at-risk workers), and in 1991 under the United States Army's Office of the Surgeon General IND 3723 (for military deployment). This PBT vaccine has been shown to be safe, with over 20,000 injections given to date, and continues to be used in at-risk individuals. During the past decade, recombinant DNA technology has been employed to develop second-generation vaccines to prevent botulism. Recombinant subunit vaccines utilizing the receptor-binding domains of botulinum neurotoxin (BoNT) have been shown to be safe and efficacious in protecting animal models against BoNT serotypes A, B, C1, D, E, and F. In 2004, the first recombinant subunit vaccine [rBV A/B (Pichia pastoris) vaccine] was tested in humans during a phase I clinical trial. Results from that study demonstrated that the recombinant bivalent vaccine was safe and well tolerated at all dosage levels tested and stimulated serotype-specific neutralizing antibodies among the majority of vaccine recipients.

Articles with similar content:

Rubella and Congenital Rubella (German Measles)
Journal of Long-Term Effects of Medical Implants, Vol.15, 2005, issue 3
William B. Long III, Richard Edlich, Kathryne L. Winters
Implementation of Revolutionary Legislation for Informed Consent for Dental Patients Receiving Amalgam Restorations
Journal of Environmental Pathology, Toxicology and Oncology, Vol.27, 2008, issue 1
Jill J. Dahlstrom, William B. Long III, Richard Edlich, Anthony T. Newkirk, Catherine L. Cross
PART II. Toxins as Therapeutic Agents
Alpha-Cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature Leading to Its Development for This Application

Critical Reviews™ in Immunology, Vol.27, 2007, issue 4
Paul F. Reid
Pandemic Preparedness for Swine Flu Influenza in the United States

Journal of Environmental Pathology, Toxicology and Oncology, Vol.28, 2009, issue 4
Jill J. Dahlstrom, William B. Long III, Shelley S. Mason, Richard Edlich, Erin M. Swainston, K. Dean Gubler
Complement in Antibody-Based Tumor Therapy
Critical Reviews™ in Immunology, Vol.34, 2014, issue 3
Matthias Peipp, Thies Rosner, Frank J. Beurskens, Stefanie Derer, Thomas Valerius